This article is more than 5 years old. Information may no longer be current.
Bioactive bone regeneration material approved for sale in Europe
Click Here to Manage Email Alerts
German company curasan AG announced that it has received European approval for its new granular bone regeneration material Ceracell.
Hans Dieter Rössler, CEO of curasan AG, stated in a press release that he considers the CE-certification of Ceracell to be another milestone in the implementation of the product offensive launched at the beginning of the year. “We are implementing our strategy of offering innovative biomaterials, customized to the needs of the users, both consistently and persistently. The launch of Ceracell in the dental market is planned to coincide with the world’s largest international dental exhibition in Cologne (IDS) at the end of March next year, and it will be launched approximately 3 months later in the orthopedic market.”
Ceracell is a synthetic, completely absorbable and bioactive bone regeneration material. Although the porosity compared to Cerasorb has been increased considerably yet again, the material has greater mechanical stability, the company reported. Thanks to the spongy structure designed after human bones and an optimized formulation, an increased number of bone-forming cells dock on Ceracell, which leads to accelerated and qualitatively better bone regeneration. Ceracell is especially suitable when the body’s own healing potency needs to be reinforced by substances for bone growth such as PRP, BMP, bone marrow or stem cells, according to the press release.